Multiple Sclerosis News TodayMS News & Notes: Briumvi, Vitamin D, CNM-Au8

In a synopsis from ACTRIMS San Diego forum at the end of February, most patients who achieved a “no evidence of disease activity” in the first 6 months of therapy with Briumvi continued to show no active disease at the 2-year mark. At the same time, high-dose vitamin D appears to have no effect in controlling MS. And a suspension of gold nanoparticles designed to increase intracellular energy production, and previously demonstrating positive effects on cognition, vision, and motor function in MS, is the focus of a new study set to begin enrolling patients with progressive forms of MS.